GSK-111476

Study Sponsor: GSK

Study Title

GSK2132231A Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients with unresectable metastatic melanoma

Medicine or Vaccine (generic name)

GSK2132231A

Sponsor Identification Number

111476

Trial Registry Identification Number(#'s)

NCT00942162 2008-004007-64

Medical Condition

Melanoma

Phase

Phase 2

Link to study details on the GSK Clinical Study Register

Link to study details on ClinicalTrials.gov (if available)

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

September 2017